17:35 , Jul 17, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Colorectal cancer Mouse studies suggest MAPKAPK2 inhibitors could help treat colorectal cancer. In a mouse model of colorectal cancer, systemic MAPKAPK2 knockout decreased tumor number, tumor volume and intestinal polyps and increased survival compared...
20:12 , Jun 15, 2018 |  BC Extra  |  Company News

Management tracks: JHL, Aclaris, CytomX

Biosimilars company JHL Biotech Inc. (Zhubei, Taiwan) hired Ellis Chu as CFO. He was managing director and head of greater China at Ion Pacific Ltd., an Asia-focused venture capital merchant bank. Dermatology company Aclaris Therapeutics...
21:06 , Apr 6, 2018 |  BioCentury  |  Finance

Smid-cap smorgasbord

While the biggest milestone of the second quarter came early and turned out to be a disappointment, investors still have plenty to look forward to in immuno-oncology. In addition, specialist investors’ current strategy of overweighting...
19:53 , Dec 22, 2017 |  BC Week In Review  |  Clinical News

FDA approves Aclaris' Eskata to treat SK

Aclaris Therapeutics Inc. (NASDAQ:ACRS) said FDA approved Eskata hydrogen peroxide topical solution 40% to treat raised seborrheic keratosis (SK). Aclaris plans to launch Eskata in the U.S. in spring 2018. It will be available as...
23:29 , Oct 6, 2017 |  BioCentury  |  Finance

High as a Kite

The acquisition of Kite Pharma Inc. by Gilead Sciences Inc. turned what would have been a flattish quarter into another period of outperformance, and relieved the cash constraints that could have prevented specialists from continuing...
23:10 , Oct 6, 2017 |  BioCentury  |  Finance

Coasting on catalysts

While buysiders do not expect any sector-moving milestones in the wake of a catalyst-heavy third quarter, they will have at least 21 Phase III milestones and 23 PDUFA dates on their radar. But the biggest...
20:42 , Sep 8, 2017 |  BC Week In Review  |  Clinical News

Aclaris submits MAA for dermatology candidate A-101

Aclaris Therapeutics Inc. (NASDAQ:ACRS) submitted an MAA under the EU decentralized procedure, with Sweden as the reference member state, for A-101 to treat seborrheic keratosis (SK). An NDA for A-101 is under FDA review with...
16:30 , Aug 18, 2017 |  BC Week In Review  |  Financial News

Aclaris prices $75M follow-on

On Aug. 10, Aclaris Therapeutics Inc. (NASDAQ:ACRS) raised $75 million through the sale of 3.3 million shares in a follow-on underwritten by Jefferies, Leerink, William Blair, Guggenheim and JMP Securities. Aclaris’ lead asset, A-101 ,...
20:44 , Aug 11, 2017 |  BC Extra  |  Financial News

Aclaris, Kura price follow-ons

Dermatology play Aclaris Therapeutics Inc. (NASDAQ:ACRS) and cancer company Kura Oncology Inc. (NASDAQ:KURA) both priced follow-ons late Thursday, raising over $125 million total. Aclaris raised $75 million though the sale of 3.3 million shares at...
07:16 , Jul 29, 2017 |  BioCentury  |  Finance

Show us your shorts

Absent any data showing a sustained impact of manipulative short selling on biotech valuations or their ability to raise capital, it is difficult to discern what direct benefit biotech companies would gain from BIO ’s...